Validation of a microsphere immunoassay for serological leptospirosis diagnosis in human serum by comparison to the current gold standard by Wynwood, Sarah et al.
RESEARCH ARTICLE
Validation of a Microsphere Immunoassay
for Serological Leptospirosis Diagnosis in
Human Serum by Comparison to the Current
Gold Standard
Sarah J. Wynwood1,2*, Mary-Anne A. Burns2, Glenn C. Graham1,3, Steven L. Weier4,
David B. McKay1, Scott B. Craig1,2,4
1 Faculty of Science, Health and Education, University of the Sunshine Coast, Sippy Downs, Queensland,
Australia, 2 WHO/OIE/FAO Collaborating Centre for Reference and Research on Leptospirosis, Queensland
Health Forensic and Scientific Services, Archerfield, Queensland, Australia, 3 Chemical Analysis Unit,
Queensland Health Forensic and Scientific Services, Archerfield, Queensland, Australia, 4 School of
Biomedical Sciences, Queensland University of Technology, Brisbane, Australia
* sarah.wynwood@health.qld.gov.au
Abstract
Amicrosphere immunoassay (MIA) utilising Luminex xMap technology that is capable of
determining leptospirosis IgG and IgM independently was developed. The MIA was validat-
ed using 200 human samples submitted for routine leptospirosis serology testing. The
traditional microscopic agglutination (MAT) method (now 100 years old) suffers from a sig-
nificant range of technical problems including a dependence on antisera which is difficult to
source and produce, false positive reactions due to auto-agglutination and an inability to dif-
ferentiate between IgG and IgM antibodies. A comparative validation method of the MIA
against the MAT was performed and used to determine the ability of the MIA to detect lepto-
spiral antibodies when compared with the MAT. The assay was able to determine samples
in the reactive, equivocal and non-reactive ranges when compared to the MAT and was
able to differentiate leptospiral IgG antibodies from leptospiral IgM antibodies. The MIA is
more sensitive than the MAT and in true infections was able to detect low levels of antibody
in the later stages of the acute phase as well as detect higher levels of IgM antibody earlier
in the immune phase of the infection. The relatively low cost, high throughput platform and
significantly reduced dependency on large volumes of rabbit antisera make this assay wor-
thy of consideration for any microbiological assay that currently uses agglutination assays.
Author Summary
Leptospirosis is a zoonotic disease caused by spirochaetes of the genus Leptospira and affects
millions of people, worldwide, each year. Laboratory diagnosis of leptospirosis currently re-
lies on methods that are flawed in many areas. Current methods are outdated, time consum-
ing and expensive. They rely on a continuous supply of animal products (rabbit anti-sera)
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and require specialist expertise and equipment. The current gold standard diagnostic assay
for leptospirosis (MAT) cannot determine IgG from IgM antibodies and relies on live cul-
tures, which presents problems in the way of maintenance and attenuation. Development of
a new diagnostic assay for serological diagnosis of leptospirosis that is specific, sensitive and
able to discriminate between IgG and IgM classes of antibodies—as well as being more cost
effective—will significantly improve the capabilities for detecting leptospirosis infections. It
will provide medical professionals with more valuable diagnostic information and public
health professionals with improved epidemiological information.
Introduction
Leptospirosis is considered to be the most widespread zoonotic disease in the world [1] with
clinical diagnosis proving challenging due to the non-specific nature of symptoms associated
with the disease. There are some 300 leptospiral serovars belonging to a number of different
serogroups. Currently there are 24 sero-groups of pathogenic leptospires based on their anti-
genic relatedness [2]. Leptospirosis was first reported in Australia in 1933 in the state of
Queensland and has since been isolated Australia wide [3] with Queensland reporting the ma-
jority of these cases (57.6%) [4]. In 2011 the reported incidence of leptospirosis in Queensland
was 3.4 cases per 100,000 people and overall in Australia the incidence was 0.84 cases per
100,000 people [5]. At present, 24 serovars of Leptospira spp are recognised in Australia and in
recent years a dramatic increase in the incidence of leptospirosis cases in Australia (particularly
Queensland) has been noted with environmental factors believed to be the main influence on
this increase [6].
Diagnosis of leptospirosis occurs at two stages—during the acute phase the live organism
can be detected by two methods. Polymerase chain reaction (PCR) testing is a useful molecular
detection tool for rapid qualitative diagnosis of leptospirosis in its earliest stage [7]. Serum or
blood samples provided for PCR testing must be collected within a precise timeframe (0–8
days post onset) to enable diagnosis. Blood culture isolation can also be utilised in the early
stages of leptospiral infection (0–10 days post onset), however this method is time consuming,
requires specialised media and equipment and can take months for a serovar specific result [8].
The immune phase of a leptospiral infection is characterised by the presence of leptospiral anti-
bodies and diagnosis is based on serological methods with the microscopic agglutination test
(MAT) considered the current gold standard [9]. If the stage of the disease is unknown, both
acute and immune phase tests are performed. Other serological test methods have previously
been developed including flow cytometry [10], complement fixation testing [11], indirect hem-
agglutination assay [12] an IgM dipstick assay [13] and an IgM enzyme-linked immunosorbent
assay (ELISA) in a number of formats [14,15]. Each of these assays has its advantages and dis-
advantages [16] and the type of assay used for diagnosis is generally dependant on the
facilities available.
Serological diagnosis of leptospirosis in humans in Queensland, Australia is currently per-
formed by screening with a commercially available leptospirosis IgM ELISA followed by the
MAT as a reference and confirmatory test. The MAT method has many disadvantages as it re-
quires specialist expertise, fresh leptospirosis cultures, is labour intensive, costly and is capable
of determining total antibody only. The current endemic routine panel for MAT testing in
Queensland, Australia consists of 16 serovars, with representatives from a number of different
serogroups. Each sample submitted for MAT is screened against this panel and any reactive
samples are then serially diluted and retested to determine an end point. Results are reported
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as a titre with the end point being the final dilution of serum at which 50% or more of the lepto-
spires are agglutinated. This assay permits the testing of up to 20 samples per day on a routine
basis. The MIA has the ability to simultaneously test large numbers of samples against large
numbers of serovars as well as determine individual IgG and IgM titres. These factors alone
would be enormously beneficial in the laboratory diagnostics and epidemiological studies
of leptospirosis.
Bead based suspension array technology (xMap, Luminex) has the capacity to multiplex up
to 500 individual analytes in a single well and has been shown to be a successful diagnostic tool
for serology in many applications [17,18,19]. This assay platform is based on magnetic coated
polystyrene beads filled with two coloured fluorescent dyes in differing ratios resulting in 500
distinct bead sets. Each bead set can be coated with a different antigen and mixed to allow the
simultaneous measurement of antibody response to up to 500 different antigens. This high-
throughput screening system allows processing of high numbers of patient samples per day. Its
speed, sensitivity, and accuracy of multiple binding events measured in the same small volume
have the potential to replace many clinical diagnostic and research methods and deliver data
on hundreds of analytes simultaneously [20]. The microsphere immunoassay (MIA) that has
been validated in this study was adapted from the method described by Luminex Corp (2000)
and can be utilised as a routine serology testing protocol for leptospirosis.
The development and validation of a high quality, reliable serological assay is pertinent to
the ability of a laboratory to sero-diagnose diseases in humans. Assay development begins with
the identification of a need for improved diagnostic capabilities and the benefits that can be ob-
tained from such an assay. A Luminex microsphere immunoassay (MIA) for leptospirosis anti-
body detection has the potential to function both as a high sensitivity, high throughput
screening assay as well as a high specificity assay for determination of serovar level antibodies.
This paper assesses the leptospirosis MIA in human samples as a screening assay to determine
reactive, equivocal and non-reactive samples. Validation is performed by comparison to the
leptospirosis IgM ELISA and the current gold standard, the microscopic agglutination test
(MAT) as the basis for defining the performance characteristics of the MIA.
Materials and Methods
Ethics
The study protocol was approved by the Public and Environmental Health Research Commit-
tee and the Humans Ethics Committee, Queensland Health Forensic and Scientific Services.
All human samples utilised in this study were de-identified and allocated a generic number.
Antigens
Sixteen Australian endemic pure leptospiral cultures, Table 1, were grown for 5–7 days in 3mL
EMJH broth at 30°C. These antigens were then quantitated using a Petroff-Hausser grid and cen-
trifuged at 4°C for 25 mins. The supernatant was removed and the pellet resuspended in 500μL
phosphate buffered saline (pH 7.5). All cultures were then diluted to obtain a concentration of
1.8 x 109 per mL. These diluted antigens were used to coat 16 individual Bio-Plex Pro Magnetic
COOH Bead-sets. Coupled beads were then checked for sensitivity and specificity using rabbit
anti-sera of known serovar and titre, obtained fromMAT results (See method below).
Serum Samples
This study utilised 200 serum samples which were selected from human serum samples sub-
mitted for routine leptospirosis serology to the WHO/FAO/OIE Collaborating Centre for
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Leptospirosis Reference and Research during 2012 and 2013. These samples were submitted
from Queensland hospitals and private laboratories. One hundred and eighty of these samples
had leptospirosis IgM ELISA reactive serology, 12 had non-reactive leptospirosis IgM ELISA
serology and the remaining 8 samples were not tested previously using leptospirosis IgM
ELISA. All leptospirosis IgM ELISA testing was performed at a Queensland hospital or private
laboratory prior to the samples being received at the WHO/FAO/OIE Collaborating Centre for
Leptospirosis Reference and Research. Routine diagnostic MAT was performed on all samples
at the WHO/FAO/OIE Collaborating Centre for Leptospirosis Reference and Research and re-
sults recorded against 16 routinely used, endemic serovars.
Forty-eight additional samples with reactive serology for Dengue Virus (24), Barmah Forest
Virus (8), Ross River Virus (8) or Rabies Virus (8) antibodies were obtained from the Queens-
land Health Public and Environmental Health Virology Laboratory. These samples had previ-
ously been tested by ELISA IgM (Dengue virus), ELISA IgG (Rabies virus) or Alphavirus
Hemagglutination Inhibition total antibody (HAI) (Ross River virus and Barmah Forest virus)
and were used to assess whether cross reactions exist in the leptospirosis MIA.
In addition to the 200 samples used for the validation, 20 sets of paired samples with a non-
reactive leptospirosis acute sample and reactive leptospirosis convalescent sample on the MAT
were also obtained and analysed using the MIA to determine a timeline for the detection of lep-
tospiral antibody. The results for these twenty additional samples are shown separately.
Bead Coupling
Leptospiral antigens were covalently coupled to individual Bio-Plex Pro Magnetic COOH bead-
sets (Table 2) using the Bio-Rad Amine Coupling kit and methods from Luminex Corp. Cou-
pling is achieved via carbodiimide reactions involving the primary amino groups on the protein
and the carboxyl functional groups on the bead surface. The bead yield per coupling reaction is
approximately 2,500 beads per well (in a 96-well microtitre plate). For optimum results in the
MIA, the coupled beads were diluted 1:4 in Triton-X detergent and 100 beads in 100μL buffer
were used for the immunoassay. Each individual coupled bead-set was diluted in phosphate
buffered saline (PBS) to give a reading of approximately 100 beads per bead-set per well. The
working dilution and specificity of each bead-set was validated prior to use in a diagnostic capac-
ity by utilising serovar-specific rabbit antisera and the IgG method as described below, substitut-
ing the secondary antibody with an anti-rabbit IgG (RPE). Bead-sets were considered to be valid
for use if the targeted serovar produced an antibody response to that specific bead-set.
Microsphere Immunoassay
Two microsphere immunoassays (IgG and IgM) were performed on 200 serum samples taken
from the routine MAT submissions which included samples with MAT titres (serial dilutions)
Table 1. Leptospiral cultures (antigens) used for assay validation.
L. Interrogans serovar Pomona L. Kirschneri serovar Grippotyphosa
L. Borgpetersenii serovar Hardjobovis L. Weilii serovar Celledoni
L. Borgpetersenii serovar Tarassovi L. Interrogans serovar Szwajizak
L. Interrogans serovar Australis L. Interrogans serovar Medanensis
L. Interrogans serovar Zanoni L. Kirschneri serovar Bulgarica
L. Interrogans serovar Robinsoni L. Interrogans serovar Copenhageni
L. Interrogans serovar Canicola L. Borgpetersenii serovar Arborea
L. Interrogans serovar Kremastos L. Weilii serovar Topaz
doi:10.1371/journal.pntd.0003636.t001
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ranging from< 1:50 (non-reactive) to 1:6400. Samples with an MAT titre between 1:50 and
1:200 were considered equivocal and samples with a titre 1:400 or above were considered reac-
tive. Pooled convalescent serum from patients with recent leptospirosis infections, confirmed
by PCR (on acute sample) and MAT, was used as the positive control serum in each micro-
sphere immunoassay. Negative patient serum, confirmed by negative PCR and serology) was
pooled and used as negative control serum. These controls were monitored each run to ensure
the assay was consistent.
A 96-well filter plate was pre-wetted with 150μL PBS per well and vacuum applied. One-
hundred μL of the diluted coupled beads were then added to each required well of the pre-wet-
ted 96-well microtitre filter plate and vacuum applied. Serum samples for the IgG immunoas-
say were diluted 1:400 in PBS in 1mL micronic tubes. One-hundred μL of the diluted samples
were added to the plate which was then incubated for 45 minutes on a shaker (750rpm) at
room temperature. The plate was then vacuum-washed three times with 150μL PBS per well.
100μL of a diluted secondary antibody (anti-human IgG) with a fluorescent tag (RPE) was
added to each well followed by a second 45 minute incubation and vacuum wash as per previ-
ous step. Finally, 150μL PBS was added to each well and the plate placed back on a shaker at
room temperature for at least 10 minutes prior to analysis.
Serum samples for the IgM immunoassay were treated with Siemens Rheumatoid factor
(RF) absorbent (at a dilution of 1:2) and diluted to a final concentration of 1:800 in PBS. The
plate was prepared as per the IgG immunoassay. The secondary antibody—anti-human IgM
with a fluorescent RPE tag—was used in this assay for conjugation.
Analysis
All plate wells were then analysed using Luminex xMap technology on a BioPlex 200 Platform.
The MIA results were reported as mean fluorescent intensity (MFI) and were deemed congru-
ent or incongruent relative to the standard of comparison (MAT). Cut-off values for reactive
samples were determined using five reactive sera for each MAT titre ranging from 1:100 to
1:6400 (Table 3), and developing a standard curve (R-Biopharm, 2012) using the titres
Table 2. Antigens and their corresponding bead-sets.
Antigen (Culture) Bio-Plex Bead-set #
L. Interrogans serovar Pomona 45
L. Borgpetersenii serovar Hardjobovis 27
L. Borgpetersenii serovar Tarassovi 35
L. Kirschneri serovar Grippotyphosa 54
L. Weilii serovar Celledoni 55
L. Interrogans serovar Copenhageni 46
L. Interrogans serovar Australis 26
L. Interrogans serovar Zanoni 28
L. Interrogans serovar Robinsoni 34
L. Interrogans serovar Canicola 52
L. Interrogans serovar Kremastos 36
L. Interrogans serovar Szwajizak 44
L. Interrogans serovar Medanensis 43
L. Kirschneri serovar Bulgarica 53
L. Borgpetersenii serovar Arborea 20
L. Weilii serovar Topaz 29
doi:10.1371/journal.pntd.0003636.t002
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obtained fromMAT testing and comparing them with the mean fluorescent intensities from
the MIA titrations. Fig. 1 shows the reactive sera MAT titres plotted against the MFI’s and the
standard curve that resulted. From this curve, cut-off points were determined (Table 4).
Positive/negative ratios were used to determine the cut-off point for non-reactive samples.
During the validation and determination of cut-off points the results reactive high and reactive
low were used to ensure that the MAT and the MIA results were comparable. All patient results
were reported as reactive, non-reactive or equivocal.
Diagnostic Sensitivity
Sensitivity (the ability of the MIA to correctly determine the presence of leptospiral antibody)
was determined by running known reactive (true positive) samples on the MIA and calculating
the proportion of reactive samples detected. True positive samples are samples known to be re-
active by paired sample testing with the Gold standard, the microscopic agglutination test.
Table 3. Positive sera used for standard curve.
MAT Titre MFI
Sample 1 Sample 2 Sample 3 Sample 4 Sample 5
1:100 (5x) 1511 1422 1586 1387 1675
1:200 (5x) 2086 1879 1999 1986 2108
1:400 (5x) 4158 3897 3956 4322 5186
1:800 (5x) 7998 7258 7985 8065 8723
1:1600 (5x) 10078 9985 10203 10406 11005
1:3200 (5x) 12037 11896 11785 12403 13875
1:6400 (5x) 15106 14759 14265 15089 15843
doi:10.1371/journal.pntd.0003636.t003
Fig 1. Standard curve for cut-off points.
doi:10.1371/journal.pntd.0003636.g001
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Diagnostic Specificity
Assay specificity was assessed using two methods. The first involves running known non-
reactive (true negative) samples and calculating the proportion of non-reactive samples
detected by the MIA. True negatives are defined as non-reactive samples known to be non-
reactive by paired sample testing with the Gold standard assay, microscopic agglutination test.
False positives are reactive samples determined by the test assay (MIA) that are non-reactive by
the gold standard.
The second test of specificity ensured that samples that have been shown to have reactive se-
rology for other pathogens are not cross reacting with the leptospirosis MIA.
Assay Repeatability
Within-run repeatability was determined by running four samples 20 consecutive times on one
assay run for both IgG and IgM assays. Two of these samples had an equivocal result for at
least one serovar on both assays, one sample had a reactive result for at least one serovar on
both assays and the remaining sample was non-reactive for all 16 serovars for both IgG and
IgM assays.
Repeatability is also monitored continuously as a quality control measure by monitoring
positive (reactive) and negative (non-reactive) controls with expected and accepted MFI ranges
for each control serum in every assay. If the control serum results were outside of these ranges,
the run was deemed to have failed and was repeated.
Results
MAT vs ELISA
Of the 200 samples tested, 180 samples were reactive for leptospirosis IgM by ELISA (Table 5).
Twelve samples were IgM ELISA non-reactive and eight samples did not have previous IgM
ELISA results; comparisons could only be made with the MAT and MIA for these eight sam-
ples. The MAT confirmed 27 of the leptospirosis IgM ELISA reactive samples had evidence of
leptospiral total antibody and suggested that the remaining 153 IgM ELISA reactive samples
were non-reactive (titre of< 1:50). These results suggest a substantial gap in the diagnostic per-
formance of the ELISA and the MAT.
MIA vs MAT
The MIA results (in mean fluorescent intensity—MFI) for the 27 MAT reactive samples also
indicated reactive serology (MFI> 1200). Of the 173 non-reactive MAT samples, 126 were
non-reactive on the MIA and the remaining 47 had low reactivity on the MIA, suggesting bet-
ter sensitivity in the MIA. The results for five of these 47 samples, which have been confirmed
as true leptospiral infections by PCR or blood culture, are shown in Table 6.
Table 4. Cut-off points for reactivity equivalents of samples.
MAT Titre MIA IgG and IgM MFI
Non-Reactive < 1:50 < 1200
Equivocal 1:50–1:200 1201–3999
Reactive Low 1:400–1:1600 4000–9999
Reactive High 1:3200 + 10000+
doi:10.1371/journal.pntd.0003636.t004
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MIA vs ELISA
The MIA detected leptospiral antibody in 74 (41%) of the 180 ELISA IgM reactive samples.
The remaining 106 ELISA IgM reactive samples were non-reactive on the MIA and the non-
reactive IgM ELISA samples were also non-reactive on the MIA. The 8 samples that were not
previously tested by ELISA were non-reactive on the MIA also (Table 5).
Paired Sample Testing
Of the 20 sets of additional paired samples with an MAT non-reactive acute sample and MAT
reactive convalescent sample, 12 of these pairs demonstrated equivocal or reactive IgMMFI re-
sults for the acute samples with a significant rise in MFI in the convalescent samples on the
IgMMIA. The results for the remaining eight pairs of samples were consistent between the
MAT and the MIA. Table 7 shows the results for the paired samples comparing the MAT titre
and the MIA IgM and IgG results. These samples were included in this study to show that IgM
can be detected earlier or, at least at the same time, by the MIA when compared with the MAT
in true leptospiral infections, as determined by a four-fold rise in serology.
Cross-Reactivity
Of the 48 reactive viral serology samples only one showed reactive IgG and IgM serology for
leptospirosis (this sample was previously reactive for Dengue virus serology) and the remaining
47 samples were non-reactive for both leptospirosis IgG and IgM.
Repeatability
The four samples used to test within-run repeatability showed comparable results in each well
across each of the 16 serovars. Table 8 shows the mean fluorescent intensity and standard devi-
ation values for each of the four samples used in the repeatability testing for one of the serovars
Table 5. Comparison of leptospirosis serology results for validation samples.
MAT (Total Ab) MIA IgG and IgM
REACT NR REACT NR
ELISA
Reactive 27 (15%) 153 (85%) 74 (41%) 106 (59%)
N = 80
Non-Reactive 0 12 0 12
N = 12
Not Tested 0 8 0 8
N = 8
doi:10.1371/journal.pntd.0003636.t005
Table 6. MIA reactive, MAT non-reactive samples.
Sample ELISA MAT MIA IgG MIA IgM PCR Blood CμLt
1 REACTIVE < 1:50 Equivocal Non-Reactive DETECTED NEGATIVE
2 REACTIVE < 1:50 Non-Reactive Equivocal DETECTED POSITIVE
3 REACTIVE < 1:50 Non-Reactive Equivocal DETECTED POSITIVE
4 REACTIVE < 1:50 Non-Reactive REACTIVE Not Done POSITIVE
5 REACTIVE < 1:50 Non-Reactive Equivocal DETECTED Not Done
doi:10.1371/journal.pntd.0003636.t006
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in the IgM immunoassay. Samples 1 and 2 were non-reactive. Sample 3 was reactive and sam-
ple 4 was in the equivocal range. The expected values were derived from comparison of the
MIA mean fluorescent intensity with MAT titres. Repeatability was assessed across one run
with one operator as, at the time of testing, only one operator was available to perform
this testing.
Table 7. Comparison of MAT and MIA sensitivity in paired samples.
Sample Pair Phase MAT Titre MIA IgM MIA IgG
1 Acute < 50 REACTIVE Equivocal
Convalescent 400 REACTIVE REACTIVE
2 Acute < 50 REACTIVE Equivocal
Convalescent 800 REACTIVE REACTIVE
3 Acute < 50 Equivocal Equivocal
Convalescent 800 REACTIVE REACTIVE
4 Acute < 50 Equivocal Non-Reactive
Convalescent 400 REACTIVE REACTIVE
5 Acute < 50 REACTIVE Non-Reactive
Convalescent 400 REACTIVE Equivocal
6 Acute < 50 REACTIVE Equivocal
Convalescent 1600 REACTIVE REACTIVE
7 Acute < 50 Non-Reactive Non-Reactive
Convalescent 800 REACTIVE REACTIVE
8 Acute < 50 REACTIVE Equivocal
Convalescent 3200 REACTIVE REACTIVE
9 Acute < 50 REACTIVE Equivocal
Convalescent > 6400 REACTIVE REACTIVE
10 Acute < 50 Non-Reactive Non-Reactive
Convalescent 800 REACTIVE Equivocal
11 Acute < 50 Equivocal Non-Reactive
Convalescent 800 REACTIVE REACTIVE
12 Acute < 50 Non-Reactive Non-Reactive
Convalescent 400 REACTIVE Equivocal
13 Acute < 50 Non-Reactive Non-Reactive
Convalescent 400 REACTIVE Equivocal
14 Acute < 50 Non-Reactive Non-Reactive
Convalescent 400 REACTIVE Equivocal
15 Acute < 50 Equivocal Equivocal
Convalescent 1600 REACTIVE REACTIVE
16 Acute < 50 Non-Reactive Non-Reactive
Convalescent 400 REACTIVE REACTIVE
17 Acute < 50 Equivocal Equivocal
Convalescent 400 REACTIVE REACTIVE
18 Acute < 50 REACTIVE Equivocal
Convalescent 800 REACTIVE REACTIVE
19 Acute < 50 Non-Reactive Non-Reactive
Convalescent 800 REACTIVE Equivocal
20 Acute < 50 Non-Reactive Non-Reactive
Convalescent 400 REACTIVE REACTIVE
doi:10.1371/journal.pntd.0003636.t007
Validation of a Novel Leptospirosis Serology Assay
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0003636 March 25, 2015 9 / 13
Discussion
The aim of diagnostic serology is to determine reactive and non-reactive samples for a particu-
lar infectious agent. By definition, a validated assay consistently provides test results that iden-
tify samples as being reactive or non-reactive for a selected analyte, and, by inference,
accurately predicts the disease status of patients with a predetermined degree of statistical cer-
tainty [21]. The aim of this study was to validate a microsphere immunoassay (MIA) using
Luminex xMap technology for diagnostic leptospirosis serology screening. The validation pro-
cess was performed using a comparative method—that is comparing the new assay with the
current gold standard assay. Sixteen leptospiral antigens have been coupled to 16 individual
magnetic bead-sets and validated as a panel for routine diagnostic leptospirosis serology. This
assay gives a qualitative result—Reactive, Equivocal or Non-Reactive and has the ability to de-
termine recent from past infection by differentiating between IgM and IgG antibodies—some-
thing that is more difficult to achieve with microscopic agglutination testing (MAT) as this test
can only determine total antibody. The class of antibody detected by the MIA can be used to
determine the stage of the infection which is valuable for clinicians as it can determine treat-
ment regimens for patients or in the case of a past infection, can suggest that something other
than leptospirosis is causing symptoms. Information regarding new infections is also vital from
a public health perspective as it can provide information on what serovars of leptospirosis are
currently circulating and indicate the areas where these infections are occurring.
All leptospirosis serology reactive samples by MAT were detected by MIA suggesting that
congruence is 100% when compared to the MAT. Results from the non-reactive samples, as
well as the paired samples suggest, however, that the MIA is more sensitive than the MAT. In
true infections (as demonstrated by paired sample serology testing with a minimum four fold
rise in titre) the MIA was able to detect low level antibody in the later stages of the acute phase
as well as pick up higher levels of IgM antibody earlier in the immune phase of the infection.
The MAT results indicated that these samples were non-reactive in the acute/early immune
phase. The MAT generally becomes positive between day 8 and day 10 of infection [22] howev-
er, results from this validation suggest that the MIA could detect antibody in the earlier stages
of infection development and increase the likelihood of the clinician submitting a convalescent
sample for confirmation of infection status.
The leptospirosis IgM ELISA has previously been shown to have poor specificity, as low as
41%, when used according to the manufacturer’s instructions [22]. All leptospirosis IgM
ELISA reactive samples tested in Queensland pathology laboratories are sent to the WHO/
FAO/OIE Collaborating Centre for Leptospirosis Reference and Research for confirmation
testing. In this study it was found that of 180 leptospirosis IgM ELISA reactive samples only
15% (27/180) of these showed reactive results on the MAT. This could be due to a lower level
of antibody which is not detected by the MAT at a dilution of 1 in 50 or a non-specific antibody
reaction. In this study, 41% (74/180) of the leptospirosis IgM ELISA reactive samples had reac-
tive IgG and/or IgM serology on the MIA, again suggesting the level of antibody in these partic-
ular samples may be too low for the MAT to detect. Also, this again shows that there may be
Table 8. Assay repeatability.
Sample Mean FI (IgM) SD Expected Value
1 104 4.99 < 1200
2 795 78.46 < 1200
3 4626 427.9 > 2000
4 1626 79.43 1201–2000
doi:10.1371/journal.pntd.0003636.t008
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some non-specific reactions occurring in the IgM ELISA, which are not seen on the MIA. The
MIA is therefore advantageous as a screening test as it reduces the large numbers of samples
that are unnecessarily sent for confirmation testing by MAT. It has also been suggested that
false positivity can also occur in the leptospirosis IgM ELISA due to the presence of persistent
IgM from past infections [23]. The MIA screening test eliminates these results by looking at
the levels of the individual IgG and IgM antibodies across paired specimens. A low level or
non-reactive IgM result and a plateaued reactive IgG would be suggestive of a past infection—
something not currently visible on the leptospirosis IgM ELISA or the MAT.
The MIA results suggest that the beads coated with leptospiral antigen are specific for lepto-
spiral antibodies and show no cross-reactivity with other viral agents. The one case in this
study where a Dengue Virus reactive serology sample also showed leptospiral antibodies is like-
ly to be a true leptospirosis infection occurring simultaneously with a Dengue Virus infection.
Leptospirosis and Dengue Virus infections are both common in northern parts of Queensland
(where this sample was from) as they are both associated with tropical and sub-tropical regions
where extreme weather events occur [24]. In many cases samples are submitted for both arbo-
virus testing (including Dengue virus) and leptospirosis testing at the same time.
The results from the MIA show that reproducibility is possible and accurate when compared
to the MAT. A major disadvantage of the MAT is attenuation of the live leptospiral cultures. It
has been shown that over time, leptospiral cultures lose their antigenicity and therefore become
less effective [25]. Also, day to day, the cultures can be different—more or less dense or con-
taminated—which makes reproducing results accurately a difficult task on the MAT. This issue
is overcome with the MIA as the antigens (leptospiral cultures) are wild type cultures with a
known passage number and are all diluted to a known concentration (1.8 x 109) prior to the
bead coupling process. This ensures that there are equal amounts of each antigen available in
every test. Another major advantage of the MIA over the MAT is that there is no need to main-
tain stocks of live leptospiral cultures for daily use. Pure cultures are only used in the MIA as
antigens for bead coupling and these antigens can be centrifuged, diluted and frozen at -20°C
for up to six months [26]. Currently, performing the MAT on a routine basis requires sub-
culturing more than 200 tubes per week, maintaining four stocks of cultures.
When comparing the MAT and the MIA the advantages of the latter are obvious. Firstly,
the MIA is less time consuming—a full plate of 88 samples can be run in around three hours.
To run the same number of samples on the MAT, it would take twice the time for a full panel
of 16 serovars excluding analysis. The MIA is also less labour intensive as it does not require
adding 16 individual cultures to each well on a 96 well plate for each individual patient. These
savings combined as well as the reagent costs suggest that the MIA is also less costly than the
MAT. An analysis of laboratory and assay costs shows that the current diagnostic serology
method (MAT) is performed at a cost of $AUD6.95 (excluding labour) to the leptospirosis ref-
erence laboratory per sample per 16 serovars [27]. In comparison, the MIA costs $AUD4.95
per sample (excluding labour) per 16 serovars. Secondly, the MIA uses a total of 7μL of serum
(2μL for the IgG assay dilutions and 5μL for the IgM assay dilutions) compared with 50μL of
serum used in the MAT. Thirdly, the MIA has the ability to detect and differentiate both IgG
and IgM antibodies whereas the MAT can only detect total antibody and cannot give an accu-
rate indication of the stage of infection in a single sample. The MIA can potentially include up
to 500 analytes in the one assay, therefore, there is potential to be able to include all known lep-
tospirosis serovars (~250) in one test at one time. Given the number of bead-sets available for
microsphere immunoassays other applications could potentially involve the inclusion of a
number of different viral and bacterial agents in one assay. For example, leptospirosis antibody
detection and Dengue Virus antibody detection could be combined into one routine
diagnostic test.
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In conclusion, the results from this validation suggest that the leptospirosis MIA is a benefi-
cial diagnostic screening tool for leptospirosis serology testing. This assay is able to determine
reactive, equivocal and non-reactive samples when compared to the MAT. It is able to differen-
tiate leptospiral IgG antibodies from leptospiral IgM antibodies which will provide vital diag-
nostic information as well as provide a better epidemiological picture. Further investigations
will include validation of each individual serovar to enable serovar specific results to be re-
ported and validation of a microsphere immunoassay for detection of leptospiral antibodies in
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